Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: Ten-Year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 - A study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group

被引:481
作者
Bijker, Nina
Meijnen, Philip
Peterse, Johannes L.
Bogaerts, Jan
Van Hoorebeeck, Irene
Julien, Jean-Pierre
Gennaro, Massimiliano
Rouanet, Philippe
Avril, Antoine
Fentiman, Ian S.
Bartelink, Harry
Rutgers, Emiel J. Th.
机构
[1] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Radiat Oncol, NL-1066 CX Amsterdam, Netherlands
[2] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Surg, NL-1066 CX Amsterdam, Netherlands
[3] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Pathol, NL-1066 CX Amsterdam, Netherlands
[4] European Org Res Treatment Canc, Ctr Data, Brussels, Belgium
[5] Ctr Henri Becquerel, Dept Surg, F-76038 Rouen, France
[6] CRLC Val DAurelle, Dept Surg, Montpellier, France
[7] Inst Bergonie, Dept Surg, Bordeaux, France
[8] Ist Nazl Tumori, Dept Surg, I-20133 Milan, Italy
[9] Guys Hosp, Dept Acad Oncol, London SE1 9RT, England
关键词
D O I
10.1200/JCO.2006.06.1366
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The European Organisation for Research and Treatment of Cancer conducted a randomized trial investigating the role of radiotherapy (RT) after local excision (LE) of ductal carcinoma-in-situ (DCIS) of the breast. We analyzed the efficacy of RT with 10 years follow-up on both the overall risk of local recurrence (LR) and related to clinical, histologic, and treatment factors. Patients and Methods After complete LE, women with DCIS were randomly assigned to no further treatment or RT (50 Gy). One thousand ten women with mostly (71%) mammographically detected DCIS were included. The median follow-up was 10.5 years. Results The 10-year LR-free rate was 74% in the group treated with LE alone compared with 85% in the women treated by LE plus RT (log-rank P <.0001, hazard ratio [HR] = 0.53). The risk of DCIS and invasive LR was reduced by 48% (P =.0011) and 42% (P =.0065) respectively. Both groups had similar low risks of metastases and death. At multivariate analysis, factors significantly associated with an increased LR risk were young age (<= 40 years; HB = 1.89), symptomatic detection (HR = 1.55), intermediately or poorly differentiated DCIS (as opposed to well-differentiated DCIS; HR = 1.85 and HR = 1.61 respectively), cribriform or solid growth pattern (as opposed to clinging/micropapillary subtypes; HR = 2.39 and HR = 2.25 respectively), doubtful margins (HR = 1.84), and treatment by LE alone (HR = 1.82). The effect of RT was homogeneous across all assessed risk factors. Conclusion With long-term follow-up, RT after LE for DCIS continued to reduce the risk of LR, with a 47% reduction at 10 years. All patient subgroups benefited from RT.
引用
收藏
页码:3381 / 3387
页数:7
相关论文
共 34 条
[1]   Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. [J].
Bartelink, H ;
Horiot, J ;
Poortmans, P ;
Struikmans, H ;
Van den Bogaert, W ;
Barillot, I ;
Fourquet, A ;
Borger, J ;
Jager, J ;
Hoogenraad, W ;
Collette, L ;
Pierart, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (19) :1378-1387
[2]   Variations in diagnostic and therapeutic procedures in a multicentre, randomized clinical trial (EORTC 10853) investigating breast-conserving treatment for DCIS [J].
Bijker, N ;
Rutgers, EJT ;
Peterse, JL ;
Fentiman, IS ;
Julien, JP ;
Duchateau, L ;
van Dongen, JA .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2001, 27 (02) :135-140
[3]   Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ [J].
Bijker, N ;
Peterse, JL ;
Duchateau, L ;
Robanus-Maandag, EC ;
Bosch, CAJ ;
Duval, C ;
Pilotti, S ;
van de Vijver, MJ .
BRITISH JOURNAL OF CANCER, 2001, 84 (04) :539-544
[4]   Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: Analysis of European organization for research and treatment of cancer trial 10853 [J].
Bijker, N ;
Peterse, JL ;
Duchateau, L ;
Julien, JP ;
Fentiman, IS ;
Duval, C ;
Di Palma, S ;
Simony-Lafontaine, J ;
de Mascarel, I ;
van de Vijver, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2263-2271
[5]  
COX DR, 1972, J R STAT SOC B, V34, P187
[6]   Breast-conserving therapy for ductal carcinoma in situ of the breast:: The French Cancer Centers' experience [J].
Cutuli, B ;
Cohen-Solal-Le Nir, C ;
de Lafontan, B ;
Mignotte, H ;
Fichet, V ;
Fay, R ;
Servent, V ;
Giard, S ;
Charra-Brunaud, C ;
Lemanski, C ;
Auvray, H ;
Jacquot, S ;
Charpentier, JC .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 53 (04) :868-879
[7]   AGE AS PROGNOSTIC FACTOR IN PREMENOPAUSAL BREAST-CARCINOMA [J].
DELAROCHEFORDIERE, A ;
ASSELAIN, B ;
CAMPANA, F ;
SCHOLL, SM ;
FENTON, J ;
VILCOQ, JR ;
DURAND, JC ;
POUILLART, P ;
MAGDELENAT, H ;
FOURQUET, A .
LANCET, 1993, 341 (8852) :1039-1043
[8]   Local recurrence after breast-conserving therapy for invasive breast cancer: High incidence in young patients and association with poor survival [J].
Elkhuizen, PHM ;
van de Vijver, MJ ;
Hermans, J ;
Zonderland, HM ;
van de Velde, CJH ;
Leer, JWH .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 40 (04) :859-867
[9]   Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program [J].
Ernster, VL ;
Barclay, J ;
Kerlikowske, K ;
Wilkie, H ;
Ballard-Barbash, R .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (07) :953-958
[10]  
Ernster VL, 2002, JNCI-J NATL CANCER I, V94, P1546